NCT03098862

PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response

Completed Last updated 22 August 2022

What this trial tests

trial in Ebola Virus Disease in 4,830 participants. Completed in 23 December 2020.

Timeline

4 September 2017

Primary endpoint
28 February 2019

23 December 2020

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4,830
Start date	4 September 2017
Primary completion	28 February 2019
Estimated completion	23 December 2020
Sites	4 locations across Liberia

Conditions studied

• Ebola Virus Disease — all drugs for Ebola Virus Disease →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 3 to 99, any sex, with Ebola Virus Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

Genes are instructions that tell the body how to work and grow. They can affect how the body responds to infection. Researchers want to learn more about genes that affect how the body responds to the Ebola virus. Some people with Ebola get very sick and die. Others do not. The research may lead to better treatments for Ebola virus and other germs.

Objective:

To look for genes that may be related to a person s chance of getting very sick after coming in contact with the Ebola virus.

Eligibility:

People at least 3 years of age who either:

Had Ebola

Had close contact with someone who had Ebola

Were in an Ebola vaccine study

Design:

Participants will have a small amount of blood taken from an arm vein by a needle.

Researchers will collect participants data from other vaccine studies they may have been in.

Participants may be asked questions about their health and social history.

Some participants will have their blood tested for the infection syphilis and HIV, the virus that causes AIDS. Participants will be told the results and will get help finding care, if necessary.

Some participants will have their blood sample tested to see if they have had Ebola in the past.

Blood samples will be stored for future research. They will be marked with a code but not with participants names.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.
   Fathi A, Dahlke C, Addo MM. · · 2019 · cited 80× · PMID 31368826 · DOI 10.1080/21645515.2019.1649532